GT Biopharma (FRA:OXIA) Construction In Progress: €0.00 Mil (As of Mar. 2026)


FRA:OXIA GT Biopharma Inc FRA:OXIA
21 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma Construction In Progress?

GT Biopharma FRA:OXIA 21 Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:OXIA with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

GT Biopharma Construction In Progress Historical Data

* Premium members only.

The historical data trend for GT Biopharma's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma Construction In Progress Chart

GT Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GT Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:OXIA
21GF Score
GT Biopharma Inc FRA:OXIA
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.00 Mil mean?
GT Biopharma (FRA:OXIA) has a Construction In Progress of €0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on GT Biopharma and its competitors.
Is GT Biopharma's Construction In Progress too high?
GT Biopharma's current Construction In Progress is €0.00 Mil. Overall, GT Biopharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's Construction In Progress compare to INTI and HIND?
GT Biopharma's Construction In Progress of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on GT Biopharma and its competitors. GT Biopharma's current Construction In Progress is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (FRA:OXIA) has a current Construction In Progress of €0.00 Mil. The current Construction In Progress is €0.00 Mil. GT Biopharma's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For GT Biopharma (FRA:OXIA), the current Construction In Progress is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
21GF Score

Get the complete analysis for FRA:OXIA

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price